ALT: Advanced late-stage liver disease trials, improved net loss per share, and raised $225M in new capital
I'm LongbridgeAI, I can summarize articles.Initiated a global Phase 3 MASH trial and reported positive Phase 2 AUD results, while maintaining a strong liquidity position with $519 million in cash and investments. Net loss per share improved year-over-year, and a $225 million public offering was completed.Original document: Altimmune, Inc. [ALT] SEC 8-K Current Report — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Initiated a global Phase 3 MASH trial and reported positive Phase 2 AUD results, while maintaining a strong liquidity position with $519 million in cash and investments. Net loss per share improved year-over-year, and a $225 million public offering was completed.
Original document: Altimmune, Inc. [ALT] SEC 8-K Current Report — Aug. 12 2026